Adagene Announces Clinical Data On Anti-CTLA-4 Monoclonal Antibody Adg116 At ESMO-IO 2021

KUALA LUMPUR, Dec 8 -- Adagene Inc (Adagene), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, has announced clinical data on its anti-CTLA-4 monoclonal antibody, ADG116, and anti-CD137 agonist, ADG106, in two poster presentations at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2021, to be held virtually and in Geneva, Switzerland from Dec 8 to 11.

According to a statement, both posters are available in the Publications section of the company’s website at www.adagene.com.

In the first presentation of results from an ongoing dose-escalation trial of monotherapy in patients with advanced metastatic tumours, ADG116 demonstrated a strong safety profile and early signals of efficacy, including dose-dependent T-cell activation and activity in treatment-resistant ‘cold’ tumours such as pancreatic and ovarian.

Additionally, a separate poster presentation describing results of pharmacodynamic (PD) biomarker analyses reinforced the potential synergy and strong T-cell activation of ADG106 in combination with the anti-PD-1 antibody toripalimab.

Adagene is also advancing ADG116 in combination with anti-PD-1 therapy (pembrolizumab or toripalimab) and with its proprietary anti-CD137 agonist (ADG106). Further, the company is evaluating a second anti-CTLA-4 antibody, ADG126, using its SAFEbody® precision masking technology in an ongoing phase 1 dose escalation as monotherapy.

“The data presented today from two of our NEObody™ clinical programs show how we are creating transformative antibody-based immunotherapies that push the limits of antibody discovery and development, overcoming liabilities with some of the most promising yet challenging immuno-oncology targets today,” said Peter Luo, Ph.D., Co-founder, Chief Executive Officer and Chairman of Adagene.

“These findings strengthen confidence in our clinical pipeline and the ability of our platform technologies to achieve unprecedented results that will ultimately benefit patient care.”

For more information, visit: https://investor.adagene.com.

-- BERNAMA